Skip to main content
Erschienen in: Osteoporosis International 6/2006

01.06.2006 | Original Article

Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation

verfasst von: F. Atamaz, S. Hepguler, M. Akyildiz, Z. Karasu, M. Kilic

Erschienen in: Osteoporosis International | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The purpose of this study was to evaluate the effects of alendronate (ALN) on bone mineral density (BMD) and bone turnover markers in patients with orthotopic liver transplantation (OLT).

Methods

In the prospective, controlled, open study with 24 months of follow-up, 98 patients with OLT were randomised to receive ALN 70 mg weekly or no ALN; calcium (Ca) 1,000 mg daily and 0.5 mcg calcitriol daily were provided to all patients. Lumbar spine (LS) and hip BMDs were measured at 6-month intervals by dual-energy X-ray absorptiometry (DEXA). Spinal radiographs were obtained to assess vertebral fractures. Additionally, bone turnover markers, serum parathyroid hormone (PTH) and biochemical parameters were determined every 3 months.

Results

Compared with the control group, the ALN group showed significant increases in BMD of the LS (5.1±3.9% vs 0.4±4.2%, p<0.05 at 12 months, 8.9±5.7% vs 1.4±4.9%, p<0.05 at 24 months), femoral neck (4.3±3.8% vs −1.1±3.1%, p<0.05 at 12 months, 8.7±4.8% vs 0.6±4.5%, p<0.05 at 24 months) and total femur (3.6±3.8% vs −0.6±4.0%, p<0.05 at 12 months, 6.2±3.8% vs 0.3±4.6%, p<0.05 at 24 months). In the ALN group, osteocalcin and urinary deoxypyridinoline (DPD) decreased significantly at the sixth month, with no further change, by −35.6% and −63.0%, on average, respectively (p<0.05). In the control group, a significant increase in biochemical markers of bone turnover was observed in comparison to baseline values (p<0.05). PTH increased within reference levels without a difference between groups. Two nonvertebral fractures (4.2%) and nine vertebral fractures (18.8%) in the control group and three vertebral fractures (6.8%) in the ALN group occurred during the follow-up. The weekly ALN was well tolerated, and no severe side effects occurred.

Conclusion

This is the first randomised study including a control group to demonstrate that weekly ALN was able to significantly increase BMD in patients with OLT when compared with Ca and calcitriol alone. However, ALN did not appear to offer protection against fractures.
Literatur
1.
Zurück zum Zitat Cheung AM (2001) Post-liver transplantation osteoporosis. J Hepatology 34:337–338CrossRef Cheung AM (2001) Post-liver transplantation osteoporosis. J Hepatology 34:337–338CrossRef
2.
Zurück zum Zitat Delmas PD (2001) Osteoporosis in patients with organ transplants: a neglect problem. Lancet 357:325PubMedCrossRef Delmas PD (2001) Osteoporosis in patients with organ transplants: a neglect problem. Lancet 357:325PubMedCrossRef
3.
4.
Zurück zum Zitat Ramsey- Goldman R, Dunn JE, Dunlop DD, et al (1999) Increased risk of fracture in patients receiving solid organ transplant. J Bone Miner Res 14:456–461PubMedCrossRef Ramsey- Goldman R, Dunn JE, Dunlop DD, et al (1999) Increased risk of fracture in patients receiving solid organ transplant. J Bone Miner Res 14:456–461PubMedCrossRef
5.
Zurück zum Zitat Crippin JS (2001) Bone disease after liver transplantation. Liver Transpl 7:27CrossRef Crippin JS (2001) Bone disease after liver transplantation. Liver Transpl 7:27CrossRef
6.
Zurück zum Zitat Epstein S (1996) Post-transplantation bone disease. The role of immunsuppressive agents on the skeleton. J Bone Miner Res 11:1–7PubMed Epstein S (1996) Post-transplantation bone disease. The role of immunsuppressive agents on the skeleton. J Bone Miner Res 11:1–7PubMed
7.
Zurück zum Zitat Smallwood GA, Wickman JM, Martinez E, et al (2002) Osteoporosis screening in an outpatient liver transplant clinic: Impact of primary immunsuppression. Transplant Proc 34:1569–1570PubMedCrossRef Smallwood GA, Wickman JM, Martinez E, et al (2002) Osteoporosis screening in an outpatient liver transplant clinic: Impact of primary immunsuppression. Transplant Proc 34:1569–1570PubMedCrossRef
8.
Zurück zum Zitat McDonald JA, Dunstan CR, Dilworth P, et al (1991) Bone loss after liver transplantation. Hepatology 14:613–619PubMed McDonald JA, Dunstan CR, Dilworth P, et al (1991) Bone loss after liver transplantation. Hepatology 14:613–619PubMed
9.
Zurück zum Zitat Porayko MK, Wiesner RH, Hay JE, et al (1991) Bone disease in liver transplant recipients: Incidence, timing, and risk factors. Transplant Proc 23:1462–1465PubMed Porayko MK, Wiesner RH, Hay JE, et al (1991) Bone disease in liver transplant recipients: Incidence, timing, and risk factors. Transplant Proc 23:1462–1465PubMed
10.
Zurück zum Zitat Riemens SC, Oostdijk A, van Doormaal JJ, et al (1996) Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidiol. Osteoporos Int 6:213–218PubMedCrossRef Riemens SC, Oostdijk A, van Doormaal JJ, et al (1996) Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidiol. Osteoporos Int 6:213–218PubMedCrossRef
11.
Zurück zum Zitat Eastell R, Dickson ER, Hodgson SF, et al (1991) Rates of vertebral bone loss before and after liver transplanttaion in women with primary biliary cirrhosis. Hepatology 14:296–300PubMedCrossRef Eastell R, Dickson ER, Hodgson SF, et al (1991) Rates of vertebral bone loss before and after liver transplanttaion in women with primary biliary cirrhosis. Hepatology 14:296–300PubMedCrossRef
12.
Zurück zum Zitat Hochberg MC, Ross PD, Black D, et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246–1254PubMedCrossRef Hochberg MC, Ross PD, Black D, et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246–1254PubMedCrossRef
13.
Zurück zum Zitat Shiraki M, Kushida K, Fukunaga M, et al (1998) A placebo-controlled, single blind study to determine to appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 45:191–210PubMed Shiraki M, Kushida K, Fukunaga M, et al (1998) A placebo-controlled, single blind study to determine to appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 45:191–210PubMed
14.
Zurück zum Zitat Millonig G, Graziadei IW, Eichler D, et al (2005) Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study. Liver Transpl 11(8):960–966PubMedCrossRef Millonig G, Graziadei IW, Eichler D, et al (2005) Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study. Liver Transpl 11(8):960–966PubMedCrossRef
15.
Zurück zum Zitat Genant HK, Wu CY, van Kuijk C, et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148PubMed Genant HK, Wu CY, van Kuijk C, et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148PubMed
16.
Zurück zum Zitat Wu CY, Li J, Jergas M, et al (1995) Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 5(5):354–370PubMedCrossRef Wu CY, Li J, Jergas M, et al (1995) Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 5(5):354–370PubMedCrossRef
17.
Zurück zum Zitat Genant HK, Jergas M, Palermo L, et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(7):984–996PubMedCrossRef Genant HK, Jergas M, Palermo L, et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(7):984–996PubMedCrossRef
18.
Zurück zum Zitat Sambrook P, Birmingham J, Kelly P, et al (1993) Prevention of corticosteroid osteoporosis-a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752PubMedCrossRef Sambrook P, Birmingham J, Kelly P, et al (1993) Prevention of corticosteroid osteoporosis-a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752PubMedCrossRef
19.
Zurück zum Zitat Cohen S, Levy RM, Keller M, et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42(11):2309–2318PubMedCrossRef Cohen S, Levy RM, Keller M, et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42(11):2309–2318PubMedCrossRef
20.
Zurück zum Zitat Adachi JD, Bensen WG, Brown J, et al (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387PubMedCrossRef Adachi JD, Bensen WG, Brown J, et al (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387PubMedCrossRef
21.
Zurück zum Zitat Adachi JD, Bensen WG, Bianchi F, et al (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23:995–1000PubMed Adachi JD, Bensen WG, Bianchi F, et al (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23:995–1000PubMed
22.
Zurück zum Zitat van den Ham EC, Kooman JP, Christiaans ML (2003) The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transp Int 16(2):82–87CrossRef van den Ham EC, Kooman JP, Christiaans ML (2003) The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transp Int 16(2):82–87CrossRef
23.
Zurück zum Zitat Ninkovic M, Love S, Tom BD, et al (2002) Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37(1):93–100PubMedCrossRef Ninkovic M, Love S, Tom BD, et al (2002) Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37(1):93–100PubMedCrossRef
24.
Zurück zum Zitat Shane E, Thys- Jacobs S, Papadopoulos A, et al (1996) Antiresoptive therapy prevents bone loss after cardiac transplantation (CTX). J Bone Miner Res 11:635 Shane E, Thys- Jacobs S, Papadopoulos A, et al (1996) Antiresoptive therapy prevents bone loss after cardiac transplantation (CTX). J Bone Miner Res 11:635
25.
Zurück zum Zitat Fan S, Almond MK, Ball E, et al (1996) Randomised prospective study demonstrating prevention of bone loss by pamidronate during the first year after renal transplantation. J Am Soc Nephrol 7:A2714 Fan S, Almond MK, Ball E, et al (1996) Randomised prospective study demonstrating prevention of bone loss by pamidronate during the first year after renal transplantation. J Am Soc Nephrol 7:A2714
26.
Zurück zum Zitat Reeves HL, Francis RM, Manas DM, et al (1998) Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4:404–409PubMedCrossRef Reeves HL, Francis RM, Manas DM, et al (1998) Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4:404–409PubMedCrossRef
27.
Zurück zum Zitat Dodidon P, Bruckner T, Hosch S, et al (2003) Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 14:82–89CrossRef Dodidon P, Bruckner T, Hosch S, et al (2003) Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 14:82–89CrossRef
28.
Zurück zum Zitat Monegal A, Navasa M, Guanabens N, et al (2001) Bone Disease after liver transplantation: A long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484–497PubMedCrossRef Monegal A, Navasa M, Guanabens N, et al (2001) Bone Disease after liver transplantation: A long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484–497PubMedCrossRef
29.
Zurück zum Zitat Vedi S, Greer S, Skingle SJ, et al (1999) Mechanism of bone loss after liver transplantation: A histomorphometric analysis. J Bone Miner Res 1999 14(2):281–287CrossRef Vedi S, Greer S, Skingle SJ, et al (1999) Mechanism of bone loss after liver transplantation: A histomorphometric analysis. J Bone Miner Res 1999 14(2):281–287CrossRef
30.
Zurück zum Zitat Feller RB, McDonald JA, Sherbon KJ, et al (1999) Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 5:407PubMedCrossRef Feller RB, McDonald JA, Sherbon KJ, et al (1999) Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 5:407PubMedCrossRef
31.
Zurück zum Zitat Crosbie OM, Freaney R, McKenna MJ, et al (1999) Predicting bone loss following orthotopic liver transplantation. Gut 44:430–434PubMedCrossRef Crosbie OM, Freaney R, McKenna MJ, et al (1999) Predicting bone loss following orthotopic liver transplantation. Gut 44:430–434PubMedCrossRef
32.
Zurück zum Zitat Monegal A, Navasa M, Guanabens N, et al (1997) Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148–154PubMedCrossRef Monegal A, Navasa M, Guanabens N, et al (1997) Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148–154PubMedCrossRef
Metadaten
Titel
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation
verfasst von
F. Atamaz
S. Hepguler
M. Akyildiz
Z. Karasu
M. Kilic
Publikationsdatum
01.06.2006
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 6/2006
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-006-0082-5

Weitere Artikel der Ausgabe 6/2006

Osteoporosis International 6/2006 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.